A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma. - Wikidata - awgldk - TriplyDB

A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.

A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.

http://www.wikidata.org/entity/Q34256006

about

Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review Better survival of renal cell carcinoma in patients with inflammatory bowel disease Induction of apoptosis by luteolin involving akt inactivation in human 786-o renal cell carcinoma cells Targeting the tumor microenvironment: from understanding pathways to effective clinical trials.Targeting of the innate immunity/inflammation as complementary anti-tumor therapies.Interleukins in glioblastoma pathophysiology: implications for therapy.Molecular-targeted agents combination therapy for cancer: developments and potentials.Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma.The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review.Targeting cancer-related inflammation in the era of immunotherapy.Membrane versus soluble isoforms of TNF-α exert opposing effects on tumor growth and survival of tumor-associated myeloid cells.Cancer-Related Systemic Inflammation: The Challenges and Therapeutic Opportunities for Personalized Medicine.

P2860

Q36270115-A3278A82-DC37-4367-A7EB-833502A5F811 Q36546056-2868C7CD-8BB3-42DA-8AC9-DAC0B663CA83 Q36622608-26328398-2546-4370-884A-D7008AA7A09C Q37274132-D7188F10-0BC5-4381-979B-710D93267127 Q37901025-A3B8EA9D-943E-4A1A-8AE3-C62E176799B7 Q38051761-D6E50BCF-35BC-49C3-A3B7-A9EC35FCFE88 Q38104670-D04DB9F5-3EAE-4B2B-A856-75F2A6E40988 Q38153283-8E2E9114-D9A5-4337-94C3-BFD461213C0A Q38910154-5524FF6E-9F30-4ADD-8776-F4D033C8C34B Q39044981-4523B192-5048-402C-85B0-F1AAB6FBE537 Q39147966-92BA31E6-3A9A-42DA-AF65-99734690F954 Q39429983-90C6F51D-0E88-4D70-9613-F38D8A87BC6C

P2860

A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.

http://www.wikidata.org/entity/Q34256006

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.

@ast

A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.

@en

A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.

@nl

type

label

A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.

@ast

A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.

@en

A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.

@nl

prefLabel

A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.

@ast

A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.

@en

A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.

@nl

P1433

Q34256006-4A032C5D-45C4-4E60-8824-006AC94A834E

P1476

Q34256006-362FB0D0-9CD7-4303-865C-FCA8C0258DB6

P2093

Q34256006-1C9571A6-C495-4162-9398-A3F2EE5CAEBB

Q34256006-22BA659B-72CD-4B56-8952-FBAEFC8B70D7

Q34256006-4B195C06-9811-4A14-95BC-7D388507A7CA

Q34256006-7930FE19-6479-48CF-AE80-E205E2CE6B6A

Q34256006-9395EB77-10A7-4CD8-92A5-5880020D82BC

Q34256006-AD29C14F-24DC-4EAD-9A39-8EC847DDFCB5

Q34256006-B34D8545-39F0-470B-A9C2-E0D0F6F5CC34

Q34256006-B8B9AA5D-74A3-45FC-A585-C0C38BE4334B

Q34256006-F49BD3F3-7082-4FFB-A391-7CB236F89009

P2860

Q34256006-00E25179-1AD5-404C-8E42-8794D347E28F

Q34256006-40AA98F2-9926-4321-9BB8-263240837F20

Q34256006-63CB9A48-5AA0-461B-8F16-F6C67E32DADC

Q34256006-6D051AA0-6369-439B-AB20-5865030635DA

Q34256006-772245BE-4BD3-42F5-B07C-392B5FD174A3

Q34256006-7E37EDFC-2716-419A-81CF-50F642670A71

Q34256006-8C19D7A8-BB38-4709-B775-EFA313F03B20

Q34256006-92A0F701-45E5-44F2-BA22-963FAA178135

Q34256006-960CE7D9-0DB0-4F62-9025-572CC73246F4

Q34256006-97551E7B-1927-4624-BD08-AF07C99E6CE2

P2888

Q34256006-4D5FD3BD-E496-433B-BE96-BC3582E8734E

P304

Q34256006-D8B9B42A-F967-4A93-B058-C93CBF65E237

P31

Q34256006-42D89BBD-6DF7-4043-AF0C-73A68884024C

P356

Q34256006-E38195E0-CAA2-4004-8176-447AC9471192

P407

Q34256006-059CE962-F080-4DC3-A875-8E0EDD96956F

P433

Q34256006-CEFC4AB2-5135-46C9-9480-0C66883A6020

P478

Q34256006-1DDDA223-877A-4BCC-A0D8-D7C778860359

P50

Q34256006-231DE589-D8CF-4943-ADF8-23DE96A33E3B

P577

Q34256006-7937EB3D-A358-47E3-8395-14C515CEC879

P5875

Q34256006-5694771A-065D-465F-80C4-8E23DC052299

P6179

Q34256006-5192CF6B-8B8B-43D7-81CC-DBFE70A113AE

P698

Q34256006-A06083D4-3BCB-4C93-9202-57411494DB48

P921

Q34256006-815E544F-4BA2-4704-B1D2-513E8A8D7861

Q34256006-B6FF4B1C-D1E2-4F72-83F2-BA120F169A65

P932

Q34256006-204EE6B0-3C70-41B8-A509-B8BADF1D5B35

P356

P1433

British Journal of Cancer

P1476

A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma

@en

P2093

B Berns

http://www.w3.org/2001/XMLSchema#string

C de Boer

http://www.w3.org/2001/XMLSchema#string

J M G Larkin

http://www.w3.org/2001/XMLSchema#string

K Edmonds

http://www.w3.org/2001/XMLSchema#string

K Thomas

http://www.w3.org/2001/XMLSchema#string

L M Pickering

http://www.w3.org/2001/XMLSchema#string

M E Gore

http://www.w3.org/2001/XMLSchema#string

M G James

http://www.w3.org/2001/XMLSchema#string

T R Ferguson

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

The TNF and TNF receptor superfamilies: integrating mammalian biology

Sorafenib in advanced clear-cell renal-cell carcinoma

Tumor necrosis factor or tumor promoting factor?

TNF-alpha in promotion and progression of cancer.

Combination systemic therapy for advanced renal cell carcinoma.

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions.

Overcoming TNF-alpha and drug resistance of human renal cell carcinoma cells by treatment with pentoxifylline in combination with TNF-alpha or drugs: the role of TNF-alpha mRNA downregulation in tumor cell sensitization.

Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials.

P2888

P304

1149-1153

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6605889

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-09-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46273864

http://www.w3.org/2001/XMLSchema#string

P6179

1002056732

http://www.w3.org/2001/XMLSchema#string

P698

20842130

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

phase II clinical trial

P932

2967062

http://www.w3.org/2001/XMLSchema#string